Offer Update
31 March 2010
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, provides the following update to shareholders. While discussions regarding a sale of one or more of the Company’s pipeline assets are continuing, Neuropharm has received confirmation from each of the companies with which it has been in discussions that none of them is currently considering making an offer for the Company. As a result, the Company is no longer considered to be in an offer period for the purposes of the Takeover Code.
As previously announced, on 10 March 2010, the Company is also making preparations for a Members’ Voluntary Liquidation of the Company.
For further information please contact:
Neuropharm + 44 (0) 1372 371 171
Robert Mansfield, Chief Executive Officer
Graham Yeatman, Chief Financial Officer
Piper Jaffray Ltd. + 44 (0) 20 3142 8700
Neil Mackison, Rupert Winckler
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court
Notes to Editors:
About Neuropharm
Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.ukfor further information.